ImmunityBio scores first Asian approval for ANKTIVA in Macau
The Macau authorization followed a regulatory review that considered prior decisions by both the US FDA) and the European Medicines Agency
The Macau authorization followed a regulatory review that considered prior decisions by both the US FDA) and the European Medicines Agency
The radiotherapy systems include TrueBeam, TrueBeam STx, VitalBeam, and Edge
It promises fewer injections for vision loss patients
Call it a major breakthrough for diagnostic imaging
Targets diabetes & obesity crisis as India grapples with soaring metabolic disorders
The once-weekly treatment targets Type 2 Diabetes Mellitus (T2DM) with demonstrated efficacy and safety
India’s largest glycolic acid manufacturer will unveil AviGa Bio HP70 on April 14, 2026
This follows a $6 million expansion in Rosenberg in 2025 and signals a major push to boost commercial capacity, expand R&D capabilities, and meet rising demand for US-based drug product manufacturing
The global, first-in-human, open-label trial will assess the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of TRI-611
The company, part of pharma powerhouse AbbVie, will showcase the findings—and the next evolution of its AA Signature framework—at AMWC 2026 in Monaco,
The announcement marks Dr. Reddy’s Day?1 entry into the GLP?1 receptor agonists therapy space and readiness to serve patients in India
KeyCi’s dermatologically tested lineup emphasizes clean formulations—vegan, cruelty-free, alcohol-free, and paraben-free—while being backed by pharmaceutical-grade research and FDA approval
Pfizer recommends that shareholders do not tender their shares in response to Tutanota’s offer
These approvals represent a defining moment for people living with classical Hodgkin Lymphoma
This linear, covalently closed, double-stranded DNA offers a rapid, cell-free alternative to traditional plasmid DNA, addressing a critical bottleneck in nucleic acid therapeutics development
The newly classified assays join Roche’s Ionify 25-Hydroxy Vitamin D total assay in a growing U.S. portfolio
RSM01, a preventive treatment targeting respiratory syncytial virus (RSV), was licensed earlier this month from the Gates Medical Research Institute
India faces a significant and growing burden of chronic respiratory diseases such as asthma, chronic obstructive pulmonary disease
Subscribe To Our Newsletter & Stay Updated